Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

References

• Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer. 2013;2013:327150. doi:10.1155/2013/32715023476782
   PubMedGoogle Scholar
• Ma JE, Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel). 2014;6(3):1328–1350. doi:10.3390/cancers603132824978436
   PubMed Web of Science ®Google Scholar
• Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–1100. doi:10.1126/science.115258618202256
   PubMed Web of Science ®Google Scholar
• Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457–463. doi:10.1016/j.jaad.2017.10.02829102486
   PubMed Web of Science ®Google Scholar
• Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49(5):832–841. doi:10.1067/S019014576661
   PubMedGoogle Scholar
• Grabowski J, Saltzstein SL, Sadler GR, Tahir Z, Blair S. A comparison of merkel cell carcinoma and melanoma: results from the California cancer registry. Clin Med Oncol. 2008;2:327–333.21892294
   PubMedGoogle Scholar
• Iyer JG, Parvathaneni U, Gooley T, et al. Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med. 2015;4(8):1161–1170. doi:10.1002/cam4.45825908228
   PubMedGoogle Scholar
• Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol. 2013;14(2):249–263. doi:10.1007/s11864-013-0225-923436166
   PubMedGoogle Scholar
• Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep. 2014;3:46–53. doi:10.1007/s13671-014-0068-z24587977
   PubMedGoogle Scholar
• Garibyan L, Cotter SE, Hansen JL, et al. Palliative treatment for in-transit cutaneous metastases of Merkel cell carcinoma using surface-mold computer-optimized high-dose-rate brachytherapy. Cancer J. 2013;19(4):283–287. doi:10.1097/PPO.0b013e31829e356623867506
   PubMedGoogle Scholar
• Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751–761. doi:10.1016/j.jaad.2010.02.05620646783
   PubMed Web of Science ®Google Scholar
• Santamaria-Barria JA, Boland GM, Yeap BY, et al. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol. 2013;20(4):1365–1373. doi:10.1245/s10434-012-2779-323208132
   PubMedGoogle Scholar
• Becker JC, Lorenz E, Ugurel S, et al. Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget. 2017;8(45):79731–79741. doi:10.18632/oncotarget.1921829108353
   PubMedGoogle Scholar
• Cowey CL, Mahnke L, Espirito J, et al. Real-world outcomes of patients with metastatic merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States. Future Oncol. 2017;13(19):1699–1710. doi:10.2217/fon-2017-018728605939
   PubMedGoogle Scholar
• NCCN Evidence Blocks™ for Merkel Cell Carcinoma V.2.2018. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for Merkel Cell Carcinoma V.2.2018. © National Comprehensive Cancer Network, Inc.; 2018 All rights reserved Available from: NCCN.org. Accessed October 29, 2018.
   Google Scholar
• Lebbe C, Becker JC, Grob JJ, et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396–2403. doi:10.1016/j.ejca.2015.06.13126257075
   PubMed Web of Science ®Google Scholar
• Iyer JG, Blom A, Doumani R, et al. Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients. J Clin Oncol. 2014;32:5s. doi:10.1200/jco.2014.32.15_suppl.9091
   PubMedGoogle Scholar
• Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294–2301. doi:10.1002/cam4.81527431483
   PubMed Web of Science ®Google Scholar
• Satpute S, Ammakkanavar NR, Einhorn LH. Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings. J Clin Oncol. 2014;32:5s: Abstract No: 9049. doi:10.1200/jco.2014.32.15_suppl.9049.
   PubMed Web of Science ®Google Scholar
• Sharma D, Flora G, Grunberg SM. Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am J Clin Oncol. 1991;14(2):166–169.2028925
   PubMed Web of Science ®Google Scholar
• Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000;18(12):2493–2499. doi:10.1200/JCO.2000.18.12.249310856110
   PubMed Web of Science ®Google Scholar
• Voog E, Biron P, Martin JP, et al. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer. 1999;85(12):2589–2595. doi:10.1002/(SICI)1097-0142(19990615)85:12<2589::AID-CNCR15>3.0.CO;2-F10375107
   PubMed Web of Science ®Google Scholar
• Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep. 2011;13(6):488–497. doi:10.1007/s11912-011-0197-521953511
   PubMed Web of Science ®Google Scholar
• Gorayski P, Tripcony L, Poulsen M. Chemotherapy compliance in high-risk Merkel cell carcinoma treated with chemoradiotherapy. Australas J Dermatol. 2017;58(1):35–41. doi:10.1111/ajd.1241926627052
   PubMedGoogle Scholar
• Kearney M, Thokagevistk K, Boutmy E, et al. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States. J Med Econ. 2018;21(12):1159–1171. doi:10.1080/13696998.2018.151708930149739
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. Label: BAVENCIO – avelumab injection, solution, concentrate. DailyMed; 10 2018 Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118. Accessed 12 2018.
   Google Scholar
• U.S. National Library of Medicine. Label: KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution. DailyMed; 11 2018 Avaialble from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287. Accessed 12 2018.
   Google Scholar
• U.S. National Library of Medicine. Label: OPDIVO- nivolumab injection. DailyMed; 11 2018 Avaialble from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394. Accessed 12 2018.
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.229124438712
   PubMed Web of Science ®Google Scholar
• Pannier A, Dunn JD. AMCP format for formulary submissions, Version 4.0. J Manag Care Spec Pharm. 2016;22(5):448.27123908
   PubMed Web of Science ®Google Scholar
• United States Department of Labor. Medical CPI. Bureau of Labor Statistics; 2018 Avaialble from: https://www.bls.gov. Accessed 8 2018.
   Google Scholar
• D’Angelo S, Russell J, Lebbe C, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma - a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;4(9):e180077. doi:10.1001/jamaoncol.2017.447329566106
   PubMed Web of Science ®Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, et al. Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37(9):693–702. doi:10.1200/JCO.18.0189630726175
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6(1):7. doi:10.1186/s40425-017-0310-x29347993
   PubMedGoogle Scholar
• Bullement A, Nathan P, Willis A, et al. Cost-effectiveness of avelumab for metastatic merkel cell Carcinoma. Pharmacoecon Open. 2019. doi:10.1007/s41669-018-0115-y
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. 2018 ASP drug pricing files. Centers for Medicare & Medicaid Services; 2018 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles.html. Accessed September 8, 2018.
   Google Scholar
• Chang A, Hunt M, Parkinson DR, Hochster H, Smith TJ. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1993;16(2):152–155.8452109
   PubMed Web of Science ®Google Scholar
• Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787–4792. doi:10.1200/JCO.2009.23.154819720897
   PubMed Web of Science ®Google Scholar
• Sun Y, Cheng Y, Hao X, et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer. 2016;16:265. doi:10.1186/s12885-016-2301-627061082
   PubMed Web of Science ®Google Scholar
• Gervais R, Le Caer H, Monnet I, et al. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501. Clin Lung Cancer. 2015;16(2):100–105. doi:10.1016/j.cllc.2014.10.00225467927
   PubMedGoogle Scholar
• Von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19(6):1743–1749. doi:10.1200/JCO.2001.19.6.174311251005
   PubMedGoogle Scholar
• Wong W, Yim YM, Cloutier M, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13(4):e0196007. doi:10.1371/journal.pone.019600729652926
   PubMed Web of Science ®Google Scholar
• Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. doi:10.3389/fphar.2017.0073029093678
   PubMed Web of Science ®Google Scholar
• US Department of Health & Human Services. Healthcare cost and utilization project. Agency for Healthcare Research and Quality. Avaialble from: https://hcupnet.ahrq.gov/#setup. Accessed September 28, 2018.
   Google Scholar
• Findacode.com. CPT codes. Findacode.com. Avaialble from: https://www.findacode.com/. Accessed September 28, 2018.
   Google Scholar
• Dimitroulis J, Rapti A, Stathopoulos GP, et al. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: A Phase III study. Oncol Rep. 2008;20(4):879–884.18813830
   PubMed Web of Science ®Google Scholar
• Loveman E, Jones J, Hartwell D, et al. The clinical and a cost effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2010;14:19. doi:10.3310/hta14410
   Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule. Centers for Medicare & Medicaid Services; 2018 Avaialble from: https://www.cms.gov/apps/physician-fee-schedule/. Accessed September 8, 2018.
   Google Scholar
• Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. Centers for Medicare & Medicaid Services; 2018 Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html. Accessed September 8, 2018.
   Google Scholar
• Steuten L, Fedorenko C, Sun Q, et al. Treatment patterns and predictors for overall survival in patients with metastatic Merkel cell carcinoma in the United States. Podium presented at the ISPOR 22nd Annual International Meeting; 5 20–24, 2017; Boston, MA.
   Google Scholar
• National population projections: United States by age, gender, ethnicity and race for years 2014–2060, released by the U.S. Census Bureau on December 10, 2014, on CDC WONDER Online Database; 2015 Avaialble from: http://wonder.cdc.gov/population-projections-2014-2060.html. Accessed August 8, 2018.
   Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advance merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–2552. doi:10.1056/NEJMoa160370227093365
   PubMed Web of Science ®Google Scholar